Clinical Trial Update: Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on lenvatinib plus tislelizumab with or without TACE as first-line treatment for unresectable hepatocellular carcinoma (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN